Literature DB >> 17133053

Corneal cross-linking-induced stromal demarcation line.

Theo Seiler1, Farhad Hafezi.   

Abstract

PURPOSE: Corneal collagen cross-linking by UVA/riboflavin (X-linking) represents a new method for the treatment of progressive keratoconus and currently is under clinical study. To avoid UVA irradiation damage to the corneal endothelium, the parameters for X-linking are set in a way that effective treatment occurs only in the first 300 microm of the corneal stroma. Here, X-linking not only strengthens the biomechanical properties of the cornea but also induces keratocyte apoptosis. To date, the effectiveness of treatment could be monitored only indirectly by postoperative follow-up corneal topographies or using corneal confocal microscopy. Here we describe a corneal stromal demarcation line indicating the transition zone between cross-linked anterior corneal stroma and untreated posterior corneal stroma. The demarcation line is biomicroscopically detectable in slit-lamp examination as early as 2 weeks after treatment.
METHODS: X-linking was performed in 16 cases of progressive keratoconus, and corneas were examined biomicroscopically and by means of corneal topography and pachymetry before and after treatment.
RESULTS: In 14 of 16 cases, a thin stromal demarcation line was visible at a depth of approximately 300 microm over the whole cornea after X-linking treatment.
CONCLUSION: This newly observed demarcation line may result from differences in the refractive index and/or reflection properties of untreated versus X-linked corneal stroma and represents an effective tool to biomicroscopically easily monitor the depth of effective X-linking treatment in keratoconus.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17133053     DOI: 10.1097/01.ico.0000225720.38748.58

Source DB:  PubMed          Journal:  Cornea        ISSN: 0277-3740            Impact factor:   2.651


  76 in total

1.  Corneal collagen crosslinking for corneal ectasia of post-LASIK: one-year results.

Authors:  Gang Li; Zheng-Jun Fan; Xiu-Jun Peng
Journal:  Int J Ophthalmol       Date:  2012-04-18       Impact factor: 1.779

2.  [Hazeformation (corneal scarring) after cross-linking therapy in keratoconus].

Authors:  C I A Herrmann; T Hammer; G I W Duncker
Journal:  Ophthalmologe       Date:  2008-05       Impact factor: 1.059

Review 3.  [Complications of corneal cross-linking].

Authors:  T G Seiler; G Schmidinger; I Fischinger; T Koller; T Seiler
Journal:  Ophthalmologe       Date:  2013-07       Impact factor: 1.059

4.  Effects of ultraviolet-A and riboflavin on the interaction of collagen and proteoglycans during corneal cross-linking.

Authors:  Yuntao Zhang; Abigail H Conrad; Gary W Conrad
Journal:  J Biol Chem       Date:  2011-02-18       Impact factor: 5.157

5.  Response to O'Brart: 'Is accelerated cross-linking the way forward? Yes or No'.

Authors:  M Tsatsos; C MacGregor; N Kopsachilis; P Hossain; D Anderson
Journal:  Eye (Lond)       Date:  2014-11-14       Impact factor: 3.775

6.  Is accelerated corneal cross-linking for keratoconus the way forward? Yes or No.

Authors:  D P S O'Brart
Journal:  Eye (Lond)       Date:  2014-11-14       Impact factor: 3.775

7.  Effect of the synthetic NC-1059 peptide on diffusion of riboflavin across an intact corneal epithelium.

Authors:  Yuntao Zhang; Pinakin Sukthankar; John M Tomich; Gary W Conrad
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-05-04       Impact factor: 4.799

8.  [Collagen crosslinking with riboflavin and UVA-light in keratoconus].

Authors:  M Kohlhaas
Journal:  Ophthalmologe       Date:  2008-08       Impact factor: 1.059

9.  Corneal collagen cross-linking.

Authors:  Mirko R Jankov Ii; Vesna Jovanovic; Ljubisa Nikolic; Jonathan C Lake; Georgos Kymionis; Efekan Coskunseven
Journal:  Middle East Afr J Ophthalmol       Date:  2010-01

10.  Collagen cross-linking using riboflavin and ultraviolet-a for corneal thinning disorders: an evidence-based analysis.

Authors:  G Pron; L Ieraci; K Kaulback
Journal:  Ont Health Technol Assess Ser       Date:  2011-11-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.